Compare DRCT & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | CNSP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | 73 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | 2021 | 2019 |
| Metric | DRCT | CNSP |
|---|---|---|
| Price | $0.57 | $2.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 79.8K | 33.9K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,694,000.00 | N/A |
| Revenue This Year | $58.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.04 | $0.73 |
| 52 Week High | $6.04 | $10.59 |
| Indicator | DRCT | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 29.44 | 32.82 |
| Support Level | $0.34 | $2.06 |
| Resistance Level | $0.61 | $3.00 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 12.54 | 6.38 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.